Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all CTLA-4 (Ipilimumab Biosimilar) products
- CTLA-4 (Ipilimumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody
- 特异性
- The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
- 产品特性
- Recombinant fully human IgG1 monoclonal antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
- 亚型
- IgG1 kappa
-
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- CTLA-4 (Ipilimumab Biosimilar)
- Abstract
- CTLA-4 (Ipilimumab Biosimilar) 产品
- 别名
- CD antibody, CD152 antibody, CELIAC3 antibody, CTLA-4 antibody, GRD4 antibody, GSE antibody, IDDM12 antibody, cytotoxic T-lymphocyte associated protein 4 antibody, CTLA4 antibody
- 物质类
- Biosimilar
- 背景
-
What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
-
You are here:
